Skip to main content

Table 4 Clinical efficacy of group A and group B

From: Effect of bevacizumab combined with chemotherapy on SDF-1 and CXCR4 in epithelial ovarian cancer and its prognosis

Group

Group A (34)

Group B (34)

P

CR

5(14.71)

11(32.35)

0.086

PR

10(29.42)

16(47.06)

0.134

SD

10(29.42)

3(8.82)

0.031

PD

9(26.47)

4(11.76)

0.123

Total effective rate of treatment [n(%)]

16(47.06)

28(82.36)

0.002